Valore202020212022202320242025TTMSpese di vendita, generali e amministrative6.93 B8.01 B8.99 B8.45 B8.6 B8.73 B8.73 BRicerca e sviluppo1.18 B1.41 B1.47 B1.34 B1.39 B1.4 B1.4 BReddito operativo7.79 B10.03 B8.39 B6.86 B7.34 B7.75 B7.75 BProventi non operativi, Totale18 M-560 M69 M701 M1.11 B864 M994 MOneri finanziari, al netto degli interessi capitalizzati553 M536 M726 M1.38 B1.39 B1.42 B1.42 BProventi non operativi, esclusi gli oneri finanziari-454 M-402 M-553 M-609 M-291 M-543 M-413 MEntrate/uscite straordinarie-81 M-694 M-104 M-65 M12 M-12 M-12 MUtile al lordo delle imposte7.22 B8.84 B7.66 B6.24 B7 B7.27 B7.27 BQuota di utile—-4 M-172 M-59 M-42 M-41 M-41 MImposte850 M1.11 B703 M284 M657 M547 M547 MInteressi di minoranza—3 M10 M-40 M3 M17 M17 MAltri proventi/oneri al netto delle imposte-340 M-190 M-524 M-604 M-508 M-455 M-455 MUtile netto al lordo delle attività cessate6.38 B7.73 B6.96 B5.96 B6.34 B6.7 B6.7 BAttività cessate———————Utile netto6.38 B7.73 B6.96 B5.96 B6.34 B6.7 B6.7 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari6.38 B7.72 B6.95 B6 B6.33 B6.7 B6.7 BUtile base per azione (EPS base)16.0919.6217.7515.5216.5817.7717.77Utile diluito per azione (EPS diluito)15.9619.4617.6315.4516.5317.7417.74Numero medio di azioni ordinarie in circolazione396 M394 M392 M386 M382 M377 M1.51 BAzioni diluite in circolazione399 M397 M394 M388 M383 M378 M1.51 BEBITDA10.12 B12.62 B11.77 B10.27 B10.45 B10.53 B13.11 BEBIT7.79 B10.03 B8.39 B6.86 B7.34 B7.75 B7.75 BCosto del fatturato———————Altri costi del venduto———————Ammortamento e svalutazione (liquidità)2.33 B2.59 B3.38 B3.41 B3.11 B2.78 B5.36 B
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain.